country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189272

Copy Link Print Information

ATR-IN-33

ATR-IN-33 is an ATR kinase inhibitor (IC₅₀ = 9.67 nM). ATR-IN-33 induces apoptosis, exacerbates DNA damage, and causes G1 phase cell cycle arrest by blocking CHK1 phosphorylation and DNA damage response signaling. ATR-IN-33 exhibits selective cytotoxicity against AML cell lines and can be used for research on acute myeloid leukemia.

For research use only. We do not sell to patients.

Formula: C₂₇H₂₅N₇O₂
Molecular Weight:479.53

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

ATR-IN-33 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

ATR

9.67
nM (IC₅₀)

Chk1

All ATM/ATR Isoforms :

All Checkpoint Kinase (Chk) Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MV4-11	GI50	0.34 μM	Antiproliferative activity against human MV411 AML cells assessed as reduction in cell viability. Antiproliferative activity against human MV411 AML cells assessed as reduction in cell viability.	42600468
MOLM-13	GI50	0.25 μM	Antiproliferative activity against human MOLM-13 AML cells assessed as reduction in cell viability. Antiproliferative activity against human MOLM-13 AML cells assessed as reduction in cell viability.	42600468
HUVEC	GI50	> 10 μM	Cytotoxicity against normal human umbilical vein endothelial HUVEC cells assessed as reduction in cell viability. Cytotoxicity against normal human umbilical vein endothelial HUVEC cells assessed as reduction in cell viability.	42600468

In Vitro

Anti-cancerApoptosisCell Cycle RegulationOthers

Anti-cancer

ATR-IN-33 (compound C7) is a potent ATR inhibitor that effectively inhibits the proliferation of MV411 and MOLM-13 AML cell lines^[1].
ATR-IN-33 exhibits good cytotoxic selectivity for AML cell lines over normal HUVEC cells^[1].

Anti-cancer

Apoptosis

ATR-IN-33 (0.2-0.8 μM; 48 h) induces apoptosis in MOLM-13 cells in a dose-dependent manner^[1].
ATR-IN-33 (0.2-0.8 μM) induces apoptotic morphological changes in MOLM-13 cells^[1].
ATR-IN-33 (0.2-0.8 μM) modulates the expression of apoptosis-related proteins in MOLM-13 cells^[1].

Cell Cycle Regulation

ATR-IN-33 (0.2-0.8 μM) promotes DNA damage and cell cycle arrest in MOLM-13 cells^[1].

Apoptosis

ATR-IN-33 (0.2-0.8 μM) induces caspase 3-mediated apoptosis in MOLM-13 cells^[1].

Others

ATR-IN-33 (0.2-0.8 μM; 48 h) promotes DNA damage and induces cell cycle arrest in MOLM-13 cells^[1].
ATR-IN-33 (various concentrations; 48 h) alters the cell cycle distribution of MOLM-13 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:

MOLM-13
Concentration:

0.2, 0.4, 0.8 μM
Incubation Time:

48 h
Result:

Induced cell cycle arrest.

Apoptosis Analysis^[1]

Cell Line:

MOLM-13
Concentration:

0.2, 0.4, 0.8 μM
Incubation Time:

48 h
Result:

Induced apoptosis in MOLM-13 cells in a dose-dependent manner.

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-inf	V_z	CL	F
Rat^[1]	5 mg/kg	i.v.	3.44 h	/	/	8032 ng/mL·h	8073 ng/mL·h	/	10.4 mL/min/kg	/
Rat^[1]	10 mg/kg	p.o.	2.66 h	2 h	452 ng/mL	4578 ng/mL·h	4592 ng/mL·h	2.43 mL/kg	10.56 mL/min/kg	28.4 %

In Vivo

ATR-IN-33 (compound C7) (5 mg/kg; i.v.) exhibits an MRT_inf value of 3.41 h in rats in pharmacokinetic study^[1].

ATR-IN-33 (compound C7) (10 mg/kg; p.o.) exhibits an MRTinf value of 5.71 h in rats in pharmacokinetic study^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Chemical Information

Molecular Weight 479.53
Formula C₂₇H₂₅N₇O₂
SMILES

CN1C=C(C(NC2=CC=C(N=C(C3=CC=CC4=C3C=CN4)N=C5N6CC7OC(CC7)C6)C5=C2)=O)N=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Li X, et al. Discovery of novel quinazoline-containing ATR inhibitor for treatment of acute myeloid leukemia. Bioorganic chemistry. 2026 Oct 05;181:110363.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

ATR-IN-33

All ATM/ATR Isoforms

All Checkpoint Kinase (Chk) Isoforms